Frank S. Czerwiec

Sparrow Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

36h-index7.8kcitations91works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic and Kidney Cyst Diseases(38), Electrolyte and hormonal disorders(15), Ion Transport and Channel Regulation(11), Hormonal Regulation and Hypertension(11), Renal and related cancers(10)

Publications89 total

Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts
Annals of the Rheumatic Diseases·2025Open Access
OR12-04 Clofutriben, an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, vs Placebo in a Phase II Trial for ACTH-dependent Cushing’s Syndrome (RESCUE)
Journal of the Endocrine Society·2025Open Access
OP0058 Effects of clofutriben, a selective 11ß-hydroxysteroid dehydrogenase type 1 inhibitor, on efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica
Annals of the Rheumatic Diseases·2025· 1 citedOpen Access
Clofutriben inhibits 11sz-hydroxysteroid dehydrogenase type 1 and improves ACTH-dependent cushing's syndrome compared with placebo in a phase II trial (RESCUE)
Endocrine Abstracts·2025
Fracture risk by cortisol excess status in patients with adrenal incidentalomas: a population-based cohort study
JBMR Plus·2025· 1 citedOpen Access
OP0335 THE 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR SPI-62 DIFFERENTIALLY MODULATES PREDNISOLONE IMMUNE AND MUSCULOSKELETAL EFFICACY AND BONE FORMATION/RESORPTION BIOMARKERS IN PATIENTS WITH POLYMYALGIA RHEUMATICA (PMR): AN INTERIM REPORT
Annals of the Rheumatic Diseases·2024
Dexamethasone Suppression Testing in a Contemporary Cohort with Adrenal Incidentalomas in Two U.S. Integrated Healthcare Systems
Biomedicines·2023· 2 citedOpen Access
SAT277 Intracellular Cortisol Control: An Approach To Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
Journal of the Endocrine Society·2023Open Access
Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing's syndrome morbidity and minimize adrenal insufficiency risk?
Endocrine Abstracts·2023
PMON72 The "RESCUE" Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
Journal of the Endocrine Society·2022Open Access
PSUN20 The ACSPIRE Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for Autonomous Cortisol Secretion and Adrenal Cushing's Syndrome
Journal of the Endocrine Society·2022Open Access
Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD
Clinical Journal of the American Society of Nephrology·2022· 18 citedOpen Access
The ACSPIRE trial: 11[beta]-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition for autonomous cortisol secretion and adrenal cushing's syndrome
Endocrine Abstracts·2022
The [ldquo]RESCUE[rdquo] Trial: 11[beta]-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
Endocrine Abstracts·2022
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
Kidney International Reports·2021· 36 citedOpen Access
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
UNC Libraries·2020Open Access
GFB-887, a TRPC5 Inhibitor, Is Safe and Well Tolerated and Engages the TRPC5 Target, Leading to Reductions in Urinary Rac1 in Healthy Subjects
Journal of the American Society of Nephrology·2020· 1 cited
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD) Consensus Workshop
American Journal of Kidney Diseases·2020· 51 citedOpen Access
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
Kidney International Reports·2020· 19 citedOpen Access
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
Kidney International Reports·2020· 7 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

John Ouyang(25), Vicente E. Torres(24), Arlene B. Chapman(24), Ronald D. Perrone(20), Ron T. Gansevoort(16), Jaime D. Blais(16), Olivier Devuyst(15), Holly B. Krasa(14), Eiji Higashihara(10), Jared J. Grantham(6), Joseph G. Verbalis(5), Cesare Orlandi(5), Dorothee Oberdhan(5), Susan E. Shoaf(5), Robert W. Schrier(4), Peter C. Harris(4), María V. Irazabal(4), Esther Meijer(4), Wen Zhou(4), Tomás Berl(3)